Considerations of treatment standardization from the procession of NCCN guideline of esophageal cancer

Chinese Journal of Cancer

Volumn 29, Issue 10, 2010, Pages 860-864

  Gao, Xian Shu ^a  

^a PEKING UNIVERSITY FIRST HOSPITAL   (China)

Author keywords

Esophageal cancer; National Comprehensive Cancer Network (NCCN); Standardized treatment

Indexed keywords

CISPLATIN; FLUOROURACIL;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CHEMORADIOTHERAPY; CHINA; CLINICAL PROTOCOL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; ESOPHAGUS CANCER; EVIDENCE BASED MEDICINE; HUMAN; INTERMETHOD COMPARISON; MEDICAL RESEARCH; MULTIPLE CYCLE TREATMENT; PRACTICE GUIDELINE; RADIATION DOSE FRACTIONATION; STANDARDIZATION; TUMOR LOCALIZATION;

EID: 79955873055     PISSN: 1000467X     EISSN: 1944446X     Source Type: Journal    
DOI: 10.5732/cjc.010.10251     Document Type: Article

References (22)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics. 2008 [J]. CA Cancer J Clin, 2008, 58(2): 71-96.
2. Zou XN, Chen WQ, Zhang SW, et al. An analysis of esophageal cancer incidence and mortality from 30 cancer registries in China, 1998-2002 [J]. Bulletin of Chinese Cancer, 2007, 16(3): 142-146. [in Chinese]
3. Liu JF, Wang QZ, Hou J. Surgical treatment for cancer of the oesophagus and gastric cardia in Hebei, China [J]. Br J Surg, 2004, 91(1): 90-98.
4. Herskovic A, Martz K, Al-Sarraf M, et al. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus [J]. N Engl J Med, 1992, 326(24): 1593-1598.
5. Cooper JS, Guo MD, Herskovic A, et al. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01) [J]. JAMA, 1999, 281(17): 1623-1627.
6. Minsky BD, Pajak T, Ginsberg RJ, et al. INT 0123 (RTOG 94-05) phase III trial of combined modality therapy for esophageal cancer: high dose (64.8 Gy) vs. standard dose (50.4 Gy) radiation therapy [J]. J Clin Oncol, 2002, 20(5): 1167-1174.
7. Stahl M, Stuschke M, Lehmann N, et al. Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus [J]. J Clin Oncol, 2005, 23(10): 2310-2317.
8. Stahl M, Wilke H, Lehmann N, et al. Long-term results of a phase III study investigating chemoradiation with and without surgery in locally advanced squamous cell carcinoma (LA-SCC) of the esophagus. 2008 ASCO Annual Meeting [J]. J Clin Oncol, 2008, 26(May 20 suppl): 4530.
9. Bedenne L, Michel P, Bouche O, et al. Chemoradiation followed by surgery compared with chemoradiation alone in squamous cacer of the esophagus: FFCD 9102 [J]. J Clin Oncol, 2007, 25(10): 1160-1168.
10. 18F-fluorodeoxyglucose positron emission tomography in esophageal cancer [J]. J Clin Oncol, 2004, 22(18): 3805-3812.
11. Flamen P, Lert A, Van Cutsem E, et al. Utility of positron emission tomography for the staging of patients with potentially operable esophageal carcinoma [J]. J Clin Oncol, 2000, 18(18): 3202-3210.
12. Flamen P, Lerut T, Haustermans K, et al. Position of positron emission tomography and other imaging diagnostic modalities in esophageal cancer [J]. Q J Nucl Med Mol Imaging, 2004, 48(2): 96-108.
13. Swisher SG, Maish M, Erasmus JJ, et al. Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer [J]. Ann Thorac Serg, 2004, 78(4): 1152-1160.
14. 18F-FDG-PET) in the identification of responders to chemoradiation therapy for the treatment of locally advanced esophageal cancer [J]. Annals of Surgery, 2006, 243(4): 472-478.
15. Weber WA, Ott K, Becher K, et al. Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging [J]. J Clin Oncol, 2001, 19(12): 3058-3065.
16. Flamen P, Van Cutsem E, Lerut A, et al. Positron emission tomography for assessment of the response to induction radiochemotherapy in locally advanced oesophageal cancer [J]. Ann Oncol, 2002, 13(3): 361-368.
17. Munden R, Macapinlac H, Erasmus J. Esophageal cancer: the role of integrated CT-PET in initial staging and response assessment after preoperative therapy [J]. J Thorac Imaging, 2006, 21(2): 137-145.
18. Cerfolio RJ, Bryant AS, Ohja B, et al. The accuracy of endoscopic ultrasonography with fine-needle aspiration, integrated position emission tomography with computed tomography, and computed tomography in restaging patients with esophageal cancer after neoadjuvant chemoradiotherapy [J]. J Thorac Cardiovasc Serg, 2005, 129(6): 1232-1241.
19. Gao XS, Qiao X, Wu F, et al. Pathological analysis of clinical target volume margin for radiotherapy in patients with esophageal and gastroesophageal junction carcinoma [J]. Int J Radiat Oncol Biol Phys, 2007, 67(2): 389-396.
20. Lin Q, Gao XS, Qiao XY, et al. Dose escalation of cisplatin with 5-fluorouracil in concurrent chemoradiotherapy for esophageal carcinoma [J]. Chin J Radiat Oncol, 2006, 15(4): 301-304. [in Chinese]
21. Shi X, Yao W, Liu T. Late course accelerated fractionation in radiotherapy of esophageal carcinoma [J]. Radiother Oncol, 1999, 51(1): 21-26.
22. Zhao KL, Shi XH, Jiang GL, et al. Late course accelerated hyperfractionated radiotherapy plus concurrent chemotherapy for squamous cell carcinoma of the esophagus: a phase III randomized study [J]. Int J Radiat Oncol Biol Phys, 2005, 62(4): 1014-1020.